Tandem Diabetes Care, Inc. (TNDM)
NASDAQ: TNDM · Real-Time Price · USD
23.85
-0.06 (-0.25%)
At close: Mar 18, 2026, 4:00 PM EDT
23.85
0.00 (0.00%)
After-hours: Mar 18, 2026, 4:02 PM EDT
Tandem Diabetes Care Stock Forecast
Stock Price Forecast
The 18 analysts that cover Tandem Diabetes Care stock have a consensus rating of "Buy" and an average price target of $27.89, which forecasts a 16.94% increase in the stock price over the next year. The lowest target is $12 and the highest is $55.
Price Target: $27.89 (+16.94%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Tandem Diabetes Care stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 3 | 3 |
| Buy | 4 | 3 | 4 | 4 | 4 | 5 |
| Hold | 11 | 11 | 10 | 11 | 12 | 10 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 17 | 16 | 16 | 17 | 19 | 18 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Hold → Buy Upgrades $21 → $33 | Hold → Buy | Upgrades | $21 → $33 | +38.36% | Mar 17, 2026 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $23 → $25 | Hold | Maintains | $23 → $25 | +4.82% | Mar 2, 2026 |
| Lake Street | Lake Street | Hold → Strong Buy Upgrades $50 | Hold → Strong Buy | Upgrades | $50 | +109.64% | Feb 23, 2026 |
| Truist Securities | Truist Securities | Hold Reiterates $24 → $27 | Hold | Reiterates | $24 → $27 | +13.21% | Feb 23, 2026 |
| Mizuho | Mizuho | Hold Maintains $21 → $22 | Hold | Maintains | $21 → $22 | -7.76% | Feb 20, 2026 |
Financial Forecast
Revenue This Year
1.10B
from 1.01B
Increased by 8.01%
Revenue Next Year
1.23B
from 1.10B
Increased by 12.14%
EPS This Year
-0.75
from -3.04
EPS Next Year
-0.03
from -0.75
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 1.1B | 1.4B | |||
| Avg | 1.1B | 1.2B | |||
| Low | 1.0B | 1.1B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 12.0% | 24.1% | |||
| Avg | 8.0% | 12.1% | |||
| Low | 2.9% | 3.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.42 | 0.58 | |||
| Avg | -0.75 | -0.03 | |||
| Low | -1.12 | -1.02 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.